echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cell Death Differ: Intestinal microflora affects the clinical outcome and treatment side effects of early breast cancer

    Cell Death Differ: Intestinal microflora affects the clinical outcome and treatment side effects of early breast cancer

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Breast cancer (BC) is the leading cause of cancer and the second leading cause of death among women.
    In addition to aging and genetic factors, environmental factors (diet, alcohol intake, endocrine disruptors, sedentary life>

    Breast cancer (BC) is the leading cause of cancer and the second leading cause of death among women.
    In addition to aging and genetic factors, environmental factors (diet, alcohol intake, endocrine disruptors, sedentary life>Breast cancer (BC) is the leading cause of cancer and the second leading cause of death among women.
    In addition to aging and genetic factors, environmental factors (diet, alcohol intake, endocrine disruptors, sedentary life>Breast cancer

    Triple negative breast cancer (TNBC) refers to breast cancer whose immunohistochemical examination results are negative for estrogen receptor (ER), progesterone receptor (PR) and the proto-oncogene Her2.
    Previous studies have shown that TNBC patients with PDL-1 expression mediated by immune checkpoint inhibitors have clinical benefit to chemotherapy .

    Immune immune checkpoint inhibitor-mediated PDL-1 expression TNBC patients have clinical benefit to chemotherapy Immune checkpoint inhibitor-mediated PDL-1 expression TNBC patients have clinical benefit to chemotherapy

    Although there is increasing evidence that specific gut microbiota can reduce systemic inflammation and the tumor microenvironment of patients receiving immunotherapy.
    However, there is no relevant data on the influence of intestinal flora on cancer immune response in TNBC.

    Metagenomics analysis of stool samples from BC patients and healthy volunteers

    Metagenomics analysis of stool samples from BC patients and healthy volunteers

    The study used shotgun metagenomics technology to identify the fecal microbiota composition of 121 samples from a total of 76 early-stage BC patients, of which 45 patients had pre- and post-chemotherapy pairs.
    This CANTO prospective study aims to document side effects related to the clinical management of BC .

    management


    Researchers mainly analyzed the relationship between baseline or post-chemotherapy stool microbiota and plasma metabolomics and the prognosis of BC patients and the side effects caused by treatment.


    The researchers further constructed immunocompetent mice colonized with BC patient microbiota to examine the clinical relevance of these findings.



    Chemotherapy significantly affects fecal microbiome composition in paired subgroup analysis

    Chemotherapy significantly affects fecal microbiome composition in paired subgroup analysis

    The results show that, compared with healthy individuals, excessive specific intestinal microbes can have a negative impact on the prognosis of BC patients, which can be adjusted by chemotherapy, and may affect the weight gain and neurological side effects of BC patients after treatment.


    These findings of the study are also worthy of prospective verification.


    Compared with healthy individuals, excessive specific intestinal microbes can have a negative impact on the prognosis of BC patients, which can be adjusted by chemotherapy, and may affect the weight gain and neurological side effects of BC patients after treatment.



    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.